Article citationsMore>>

J. Keane, S. Gershon, R. P. Wise, E. Mirabile-Levens, J. Kasznica, W. D. Schwieterman, et al., “Tuberculosis Assoicated with Infliximab, a Tumor Necrosis Factor AlphaNeutralizing Agent,” The New England Journal of Medicine, Vol. 345, No. 15, 2001, pp. 1098-1104.
http://dx.doi.org/10.1056/NEJMoa011110

has been cited by the following article:

• TITLE: Tenosynovitis and Sporotrichoid Disease Due to M. marinum on a Patient under Anti-TNFα Therapy

  AUTHORS: Diana Póvoas, J. Machado, F. Maltez

  KEYWORDS: Mycobacterium marinum; Anti-TNFα Drugs

  JOURNAL NAME: Advances in Infectious Diseases, Vol.3 No.4, December 19, 2013

  ABSTRACT: There have been several reports of tuberculosis (TB) and, less frequently, of nontuberculous mycobacterial (NTM) infections in association with tumor necrosis factor α inhibitor (anti-TNFα) therapy. Mycobacterium marinum is a NTM with a distinct epidemiology and is infrequently responsible for disease in humans. Most commonly, it causes localized skin infections, but in 20% to 40% of cases, it involves deeper structures. Disseminated disease is exceptional and has been reported to occur only in immunocompromised patients. The authors report a clinical case of tenosynovitis and sporotrichoid disease due to M. marinum in a 45-year-old male patient under anti-TNFα therapies for spondyloarthropathy. Along antimicrobial therapy, the patient underwent surgical debridement and after two years he is still on treatment but substantially improved. A few cases of M. marinum infection occurring in patients treated with anti-TNFα drugs have been reported. The diagnosis of infection due to M. marinum requires a high index of suspicion from a properly obtained exposure history and is important so that efficient diagnostic approach and treatment are ensured.